Healthcare Biz Recap: Alexion ENJOYS Acquisition Chatter, Rosetta Genomics SLIDES

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares bumped up on chatter that Roche (RHHBY.PK) might offer as much as $128 per share for the company, greatly outstripping its $106 price at Friday’s close. Such a price could be quite expensive, given that the firm has only one commercially approved drug, Solaris, whose claim to fame is that it’s said to be the most expensive drug on the market, with an average cost of more than $400,000 per patient.

Rosetta Genomics Ltd. (NASDAQ:ROSG) shares fell significantly following its 5.5 million share offering at $5, which represents a 13 percent discount to Thursday’s close. The placement pricing is way down from its initial filing in June, above $12. The gross proceeds should amount to around $27.5 million, which the firm intends to use to fund its operations, along with other general corporate purposes.

Shares of PerkinElmer, Inc. (NYSE:PKI) jumped after exceeding its second quarter earnings target Friday morning. Net earnings rose by 13% year-over-year on double-digit revenue growth in its health care division and stronger margins. Revenue from its human health unit increased 18 percent, but its environmental health business experienced only a 1.2 percent rise.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.